Celldex Therapeutics, Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-12-08

Reporting Person: Cavanaugh Sarah (SVP of Corp Affairs & Admin.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	M	1857	$9.0165	Acquired	2265	Direct
2021-12-08	Common Stock	M	5466	$10.38	Acquired	7731	Direct
2021-12-08	Common Stock	S	7323	$40.00	Disposed	408	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Incentive Stock Option (Right to Buy)	$9.0165	M	1857	Disposed	2028-06-13	Common Stock (1857)	Direct
2021-12-08	Incentive Stock Option (Right to Buy)	$10.38	M	5466	Disposed	2030-06-18	Common Stock (5466)	Direct

Footnotes

F1: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.

F2: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F3: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.